+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oral Proteins and Peptides Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941071

Global Oral Proteins and Peptides Market Outlook

The global oral proteins and peptides market size was valued at USD 2.52 billion in 2023, driven by increasing prevalence of diabetes and gastrointestinal disorders across the globe. The market size is anticipated to grow at a CAGR of 14.5 % during the forecast period of 2024-2032 to achieve a value of USD 8.3 billion by 2032.

Oral Proteins and Peptides: Introduction

The Oral Proteins and Peptides market involves the development and distribution of protein and peptide-based therapeutics designed for oral administration. These biomolecules offer potential treatments for various diseases, including diabetes, gastrointestinal disorders, and others. Oral delivery is preferred for its convenience and non-invasive nature but poses challenges due to protein and peptide degradation in the digestive system. Advances in drug formulation and delivery technologies aim to overcome these barriers, enhancing bioavailability and therapeutic effectiveness.

Key Trends in the Global Oral Proteins and Peptides Market

Efforts are being intensified to develop efficient delivery mechanisms to protect proteins and peptides from digestive enzymes and improve absorption in the gastrointestinal tract. Technologies like nanoparticle encapsulation and permeability enhancers are gaining traction.

Initially concentrated in areas like diabetes and gastrointestinal disorders, the scope of oral proteins and peptides is broadening to include a wider range of therapeutic areas, including autoimmune diseases and cancers.

The convenience and non-invasive nature of oral administration are in line with the increasing demand for patient-centric treatment options, driving research and acceptance of oral proteins and peptides.

Pharmaceutical companies are increasingly collaborating with biotech firms and academic institutions to leverage expertise in drug development and commercialization, accelerating the introduction of innovative products.

Regulatory bodies are acknowledging the potential of oral proteins and peptides, leading to streamlined pathways for approval, especially for treatments addressing unmet medical needs.

The ease of administration and storage of oral formulations align with global health goals to improve access to essential medicines, particularly in low-resource settings.

Global Oral Proteins and Peptides Market Segmentation

Market Breakup by Drug Type

  • Plecanatide
  • Linaclotide
  • Octreotide
  • Calcitonin
  • Insulin

Market Breakup by Application

  • Gastric and Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

Market Breakup by End User

  • Hospitals
  • Ambulatory Surgical Centre
  • Clinics

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Oral Proteins and Peptides Market Overview

In North America, the oral proteins and peptides market is propelled by advanced biotechnological research, a strong pharmaceutical industry, and substantial healthcare spending. The region leads in innovative drug delivery system developments and patient-centric drug design, focusing on improving the bioavailability and efficacy of oral protein and peptide therapeutics. There's also a significant emphasis on regulatory compliance and intellectual property rights, fostering a competitive and dynamic market environment.

Europe's market benefits from a robust healthcare research infrastructure, stringent regulatory standards, and a focus on advanced pharmaceutical innovation. The region shows a strong commitment to developing novel drug delivery technologies, including oral proteins and peptides. Collaborative research efforts, supported by public and private funding, contribute to the exploration of new treatments for chronic diseases. The market is also influenced by policies aimed at ensuring patient safety and high-quality pharmaceutical products.

The market in the Asia-Pacific region is rapidly growing, driven by increasing healthcare investments, a rising prevalence of chronic diseases, and improvements in biopharmaceutical research capabilities. Countries like China, India, and Japan are becoming significant players in the pharmaceutical industry, focusing on both innovative research and the production of generic drugs. The market's growth is further fueled by a growing middle class, increasing healthcare awareness, and expanding access to healthcare services.

Global Oral Proteins and Peptides Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Novo Nordisk A/S
  • Synergy Pharmaceuticals Inc.
  • Chiasma Inc.
  • Tarsa Therapeutics Inc.
  • Biocon Limited
  • Generex Biotechnology Corp.
  • AstraZeneca PLC
  • Proxima Concepts Limited
  • Oramed Pharmaceuticals Inc.
  • Allergan Plc.
  • Generex Biotechnology Corp.
  • Hoffmann-La Roche
  • Sanofi
  • Bristol-Myers Squibb Company
  • Hovione


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Oral Proteins and Peptides Market Overview
3.1 Global Oral Proteins and Peptides Market Historical Value (2017-2023)
3.2 Global Oral Proteins and Peptides Market Forecast Value (2024-2031)
4 Global Oral Proteins and Peptides Market Landscape
4.1 Global Oral Proteins and Peptides Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Oral Proteins and Peptides Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Products
5 Global Oral Proteins and Peptides Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis`
6 Global Oral Proteins and Peptides Market Segmentation
6.1 Global Oral Proteins and Peptides Market by Drug Type
6.1.1 Market Overview
6.1.2 Plecanatide
6.1.3 Linaclotide
6.1.4 Octreotide
6.1.5 Calcitonin
6.1.6 Insulin
6.2 Global Oral Proteins and Peptides Market by Application
6.2.1 Market Overview
6.2.2 Gastric and Digestive Disorders
6.2.3 Bone Diseases
6.2.4 Diabetes
6.2.5 Hormonal Disorders
6.3 Global Oral Proteins and Peptides Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Ambulatory Surgical Centre
6.3.4 Clinics
6.4 Global Oral Proteins and Peptides Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Oral Proteins and Peptides Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Oral Proteins and Peptides Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Oral Proteins and Peptides Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
1.1 ASEAN
9.5 Others
10 Latin America Oral Proteins and Peptides Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Oral Proteins and Peptides Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Novo Nordisk A/S
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Synergy Pharmaceuticals Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Chiasma Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Tarsa Therapeutics Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Biocon Limited
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Generex Biotechnology Corp.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 AstraZeneca PLC
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Proxima Concepts Limited
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Oramed Pharmaceuticals Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Allergan Plc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Generex Biotechnology Corp.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Hoffmann-La Roche
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Sanofi
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Bristol-Myers Squibb Company
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 Hovione
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Oral Proteins and Peptides Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Novo Nordisk A/S
  • Synergy Pharmaceuticals Inc.
  • Chiasma Inc.
  • Tarsa Therapeutics Inc.
  • Biocon Limited
  • Generex Biotechnology Corp.
  • AstraZeneca PLC
  • Proxima Concepts Limited
  • Oramed Pharmaceuticals Inc.
  • Allergan Plc.
  • Generex Biotechnology Corp.
  • Hoffmann-La Roche
  • Sanofi
  • Bristol-Myers Squibb Company
  • Hovione

Methodology

Loading
LOADING...

Table Information